Actively Recruiting
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-01-07
53
Participants Needed
1
Research Sites
339 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to look at how safe 89Zr-DFO-SC16.56 is, and how it is processed by the body in people with small cell lung cancer.
CONDITIONS
Official Title
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed, informed consent
- Age 4 or more years
- Histologically confirmed small cell lung cancer (new or recurrent), small cell carcinoma of unknown or non-lung origin, or other neuroendocrine tumors
- Histologically confirmed prostate cancer with suspected or confirmed neuroendocrine prostate cancer
- Histologically confirmed or suspected primary brain tumor
- Diagnosed with specific tumors like desmoplastic small round cell tumors, osteosarcoma, Ewing's sarcoma, rhabdomyosarcoma, Wilms tumors, hepatoblastomas, rhabdoid tumors, or neuroblastoma
- At least one tumor lesion on CT or MRI measuring 0.8 cm or larger, or detectable tumors on PET, SPECT, or bone scans within the last 12 weeks
- ECOG performance status between 0 and 2
- Lansky performance score of at least 40 for participants under 16 years
- Negative serum pregnancy test within 2 weeks before receiving the drug for women who can become pregnant
- Availability of tumor tissue suitable for DLL3 testing or plans to obtain such tissue as part of standard care
- For prostate cancer patients with only bone metastases, recent imaging showing active bone tumors within the last 8 weeks
You will not qualify if you...
- History of severe allergic reactions to human or humanized antibodies
- Pregnant or breastfeeding women
- Psychiatric illness that would prevent following study procedures
- Unable to undergo PET scan due to weight limits
- Need for anesthesia or sedation to tolerate PET scan procedure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
Research Team
M
Mark P Dunphy, DO
CONTACT
C
Charles Rudin, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here